Telix Pharmaceuticals (ASX: TLX) has made a number of new leadership appointments as part of an internal reorganisation to align its operations across four business units, reflecting its focus as a therapeutics-led radiopharmaceutical company committed to precision oncology.
The updated business model comprises: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech) and Telix Manufacturing Solutions (TMS).
As part of this initiative, the company had announced three leadership changes:
- Richard Valeix, Chief Executive Officer, Telix Therapeutics (formerly Group Chief Commercial Officer), leading the company’s therapeutic pipeline commercialisation and business development;
- Kevin Richardson, Chief Executive Officer, Telix Precision Medicine (formerly Chief Executive Officer, Americas), leading the development of the company’s diagnostics, global marketing and commercial operations in the U.S. and Canada;
- Raphael Ortiz, Chief Executive Officer, Telix International, leading the “rest of world” commercial operations for Europe, Middle East and Africa (EMEA), Asia Pacific (APAC) and Latin America regions (formerly Chief Executive Officer, EMEA & APAC).
Darren Patti remains Group Chief Operating Officer, with leadership responsibility for Telix’s internal manufacturing operations, including the operations of ARTMS, IsoTherapeutics and Optimal Tracers, which sit under the TMS umbrella.
Dr Christian Behrenbruch, Telix Managing Director and Group Chief Executive Officer said the new structure will optimise the development and commercialisation of theranostic radiopharmaceuticals.
“Telix is at an inflection point: momentum in our therapeutics business is growing, with prostate, kidney and brain cancer therapeutic candidates currently in, or advancing to, pivotal clinical trials. Precision medicine is our global commercialisation engine, to bring personalised, theranostic solutions to market and is underpinned by a growing manufacturing footprint that enables enhanced control over the supply chain.
“ Telix is evolving, and the revised business model reflects our differentiated position, harnessing the power of targeted radiation at every step of the patient journey.”
